Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Entera Bio Ltd.
  6. Summary
    ENTX   IL0011429839

ENTERA BIO LTD.

(ENTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
4.16(c) 5.19(c) 4.42(c) 4.56(c) 4.51 Last
1 988 218 5 086 190 948 311 340 154 439 994 Volume
+11.53% +24.76% -14.84% +3.17% -1.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,24 M - -
Net income 2021 -18,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,63x
Yield 2021 -
Sales 2022 0,36 M - -
Net income 2022 -18,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,87x
Yield 2022 -
Capitalization 108 M 108 M -
Capi. / Sales 2021 446x
Capi. / Sales 2022 305x
Nbr of Employees 19
Free-Float 70,3%
More Financials
Company
Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery... 
More about the company
Ratings of Entera Bio Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ENTERA BIO LTD.
06/17ENTERA BIO  : Gets European Union Patent for Oral Parathyroid Hormone; Stock Jum..
MT
06/17ENTERA BIO  : ‒ Oral delivery technology has potential to transform $20 bi..
PU
06/17ENTERA BIO  : Receives Foundational Patent for its Oral PTH using its Platform O..
AQ
06/17ENTERA BIO  : See article
PU
06/16ENTERA BIO  : B. Riley Starts Entera Bio at Buy with $9 PT, Notes Lead Program's..
MT
05/20ENTERA BIO  : Reports First Quarter 2021 Financial Results and Provides Clinical..
PU
05/20ENTERA BIO  : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS..
PU
05/20Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical..
GL
04/20Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Direc..
GL
04/15ENTERA BIO  : Names US CFO
MT
04/15Entera Appoints Ramesh Ratan as Chief Financial Officer
GL
04/06New Data Suggest Entera's Platform Orally Delivers Human Growth Hormone, Stud..
GL
03/22ENTERA BIO  : Aegis Capital Initiates Entera Bio at Buy Rating With $12 Price Ta..
MT
03/18Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quart..
GL
03/12MIDDAY REPORT : Wall Street Mixed Midday As Bond Yields Surge Again
MT
More news
News in other languages on ENTERA BIO LTD.

- No features available -

More news
Analyst Recommendations on ENTERA BIO LTD.
More recommendations
Chart ENTERA BIO LTD.
Duration : Period :
Entera Bio Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENTERA BIO LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,56 $
Average target price 10,33 $
Spread / Average Target 127%
EPS Revisions
Managers and Directors
NameTitle
Spiros Jamas Chief Executive Officer & Director
Dana Yaacov-Garbeli Chief Financial Officer
Gerald M. Lieberman Independent Chairman
Phillip Schwartz Director, EVP, President-Research & Development
Arthur C. Santora Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ENTERA BIO LTD.322.22%108
GILEAD SCIENCES, INC.15.60%84 469
WUXI APPTEC CO., LTD.24.70%66 143
REGENERON PHARMACEUTICALS10.59%55 327
BIONTECH SE177.34%54 605
VERTEX PHARMACEUTICALS-20.58%48 589